 Sample
& Assay Technologies QIAGEN – Digene: Creating a Leader in MDx, June 4, 2007 - 1 - QIAGEN & Digene Announce Merger The New Market and Technology Leader in Molecular Diagnostics Employee Meeting Digene Gaithersburg, June 4th 2007 June 4, 2007, 1:00am EST Filed by: QIAGEN N.V. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 under the Securities Exchange Act of 1934 Subject Company: Digene Corporation Exchange Act File No. 000-28194 |
 Sample
& Assay Technologies - 2 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics . QIAGEN and Digene announced yesterday to combine the two companies to create the market and technology leading company in molecular diagnostics . The Boards of Directors of both companies approved the transaction in which QIAGEN is to acquire 100% of Digene’s stock . This strategic transaction combines QIAGEN’s leading portfolio of sample & assay technologies with Digene’s leadership in HPV and cancer-targeted molecular diagnostic testing This creates a global leader with over $350 million of molecular diagnostics revenue and $700 million overall. |
 Sample
& Assay Technologies - 3 - QIAGEN/Digene – Creating a Leader in MDx Combined Revenue Distribution – Highly Complementary Based on Q1 2007 By Product Groups By Geographic Regions By Customer Groups Europe 46% North America 39% Asia 13% North America 85% EU 12% North America 52% EU 36% Asia 9% Consumables 89% Consumables 92% Consumables 90% Instruments 10% Instruments 8% Instruments 10% MDx 100% MDx 48% MDx 27% Pharma 24% Pharma 17% AT 11% AT 8% Biomedical 18% Research 20% All figures are estimates + RoW Research 27% |
 Sample
& Assay Technologies - 4 - QIAGEN/Digene – Creating a Leader in MDx 0 50 100 150 200 250 2003 2004 2005 2006 2007E 0 5 10 15 20 25 30 35 40 45 Revenues Operating income QIAGEN and Digene at a Glance Revenues excluding the synthetic DNA business unit, sold in Q2 2004 Market- and technology leader in Sample & Assay Technologies Founded: 1984 Headquarters: Hilden, Germany Germantown, MD Employees: 1,900 International subs: 29 Rev 2006 (US$ m) 466 Listing: NASDAQ: QGEN Frankfurt: QIA Absolute market leadership in HPV MDx testing, only FDA approved test Founded: 1987 Headquarters: Gaithersburg, MD Employees: 570 International subs: 7 Rev 2006 (US$ m) 153 Listing: NASDAQ: DIGE Digene figures converted to calendar year (CY) 0 50 100 150 200 250 300 350 400 450 500 550 2003 2004 2005 2006 2007E 0 20 40 60 80 100 120 140 160 Revenues Operating income Revenues CAGR 2003-2006 15% Revenues CAGR 2003-2006 32% |
 Sample
& Assay Technologies - 5 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics Highly Synergistic Capabilities and Assets Sales (Q1*4) 512 210 Sales in MDx (approx) 154 210 Sales strength Global North America Sales force size in MDx 150 120 Sales force target in MDx Clinical Laboratories Clinical Laboratories, Physicians Assay portolio Broad: 120 tests: virology, microbiology, genetic, pharmacogenetic HPV Technology portfolio Strong - sample and assay technologies HC2 Operations US, D, CH, CN US Employees 1990 570 |
 Sample
& Assay Technologies - 6 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics Who is QIAGEN? What is our strategy? What do we do in Diagnostics? |
 Sample
& Assay Technologies - 7 - QIAGEN/Digene – Creating a Leader in MDx 2.000 QIAGEN Employees in 23 Countries |
 Sample
& Assay Technologies - 8 - QIAGEN/Digene – Creating a Leader in MDx Global Set-up With Three Headquarters In Major Markets Maryland Shanghai/Shenzen Düsseldorf Switzerland = Automation Center of Excellence Hamburg = Assay Center of Excellence Valencia (1) = Customer satisfaction center Singapore = Customer satisfaction center Shenzen = Certified Production (2) 23 Subs = Direct sales and marketing (1) California (2) Certified by the chinese regulatory authorities SDA for production of diagnostic products |
 Sample
& Assay Technologies - 9 - QIAGEN/Digene – Creating a Leader in MDx USA: Country with Biggest Sales Organization Number of Employees in Sales: 770 Direct Sales Australia Canada France Germany Italy Japan Switzerland UK USA Netherlands Belgium China Norway Austria Sweden Malaysia Denmark Finland Singapore Korea Turkey Luxemborg Hong Kong Focus 2006: Asia and especially China Focus 2007: South America, South Africa and Eastern Europe
|
    Sample
& Assay Technologies - 10 - QIAGEN/Digene – Creating a Leader in MDx What is important to us? 3i‘s: Identity - Inspire - Impact Identity Culture nspire Leadership I D E N T I T Y D E N Y I mpact Management T I T 1. Create and take ownership 2. Courage 3. Lead, motivate and empower 4. Be a role model 5. Communicate 1. Act with Passion 2. Value Integrity 3. Improve Continuously 4. Create Value 5. Strive for Excellence 1. Transparency 2. Delegate 3. Set up the right priorities 4. Decide, execute and monitor! 5. Act as entrepreneurs |
    Sample
& Assay Technologies - 11 - QIAGEN/Digene – Creating a Leader in MDx What Is Important To Us? Our Culture 1. Act with Passion: We act with passion engagement and enthusiasm 2. Value Integrity: We are committed to integrity and respect for our customers, colleagues, partners
and shareholders 3. Improve Continuously: We continually improve in order to drive breakthroughs in health care and sciences 4. Create Value We use our global reach, our creativity, innovation and scientific excellence to
exceed our and our customer’s expectations and thereby create
value 5. Strive for Excellence: We seek to attract exceptional people whose individual strength and skills are the
basis for excellent teams. We provide them with opportunities for personal
and professional growth IDENTITY – Our DNA Our leadership reflects our commitment to our identity Identity Culture |
 Sample
& Assay Technologies - 12 - QIAGEN/Digene – Creating a Leader in MDx Very High Committment to our Employees . Learning organization - “Investing in you” program Basic and advanced trainings Leadership programs Management campus and QIAGEN MBA . International careers Working in global teams Short- and mid-term Expatriates program . Families and social activities Sabatical programs Kindergarten Get-to-gethers . Competitive compensation All employees are shareholder |
       Sample
& Assay Technologies - 13 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics Who is QIAGEN? What is our strategy? What do we do in Diagnostics? |
 Sample
& Assay Technologies - 14 - QIAGEN/Digene – Creating a Leader in MDx Providing Sample Preparation & Assay Technologies |
     Sample
& Assay Technologies - 15 - QIAGEN/Digene – Creating a Leader in MDx Mission: Leader in Sample and Assay Technologies QIAGEN 2007 SAMPLE TECHNOLOGIES ASSAY TECHNOLOGIES . Market and innovation leadership Sample technologies Assay technologies . Strong base in Academic Research Setting standards Source of new innovation . Focus area addresses rapid growth markets Molecular diagnostics Applied Testing Pharma |
 Sample
& Assay Technologies - 16 - QIAGEN/Digene – Creating a Leader in MDx SAMPLE TECHNOLOGIES ASSAY TECHNOLOGIES Sample collection Sample stabilization Sample transport Sample disruption Targeted lysis Target capture Sample purification Inhibitor removal/inactivation Enrichment/deletion of target Sample prep for crystallography Sample prep for MALDI mass spec Nucleic acid denaturation Natural target amplification In vitro target amplification Whole genome amplification MDA Methylation/Epigenetics Quantitation methods Separation of haploids Quality control methods etc. Enzyme technologies Chemical enhancements Formulation Enzyme activation/inhibition Endpoint PCR Real-time PCR Mulitplex QIA-Plex Fast-PCR Isothermal amplification technologies Assay design technologies Primer selection Probe selection RNAi assays Transfection Rolling Circle Amplification RCAT Signal amplification Luminex Assay acceleration chemistries etc. General and Supporting Technologies Instrumentation Software Plastic Manufacturing technologies Packaging technologies Microfluidic technologies etc. IP (12/05): 409 issued, 321 pending patents >500 under license QIAGEN Technology and Innovation Sample Assay Technologies |
         Sample
& Assay Technologies - 17 - QIAGEN/Digene – Creating a Leader in MDx Disseminating Technologies Into Four Markets Product and Technology Continuum Academia Life Science Research Applied Testing Molecular Diagnostics Pharma Research & Development Sample Assay SAMPLE Technologies ASSAY Techologies |
 Sample
& Assay Technologies - 18 - QIAGEN/Digene – Creating a Leader in MDx Bringing Full Power To Our Customers Globally aligned Sales and Marketing Customer focused – scaleable – critical mass One core = multiple channels We are Life Sciences Sales Pharma Key Account Manager Applied Testing Sales Developer MDx Sales SAMPLE TECHNOLOGIES ASSAY TECHNOLOGIES Diagnostic Pharma Biotech Academia Veterinary Forensics Food Diagnostics Sales Specialists AT Sales Developers Pharma KAMs Life Sciences Sales Life Sciences Marketing Manager Pharma Marketing Manager Applied Testing Marketing Manager Diagnostic Marketing Manager Customer Sales force Marketing force Sample Assay |
 Sample
& Assay Technologies - 19 - QIAGEN/Digene – Creating a Leader in MDx MDx And Applied Testing Account For 35% Revenue breakdown for segments Focus provides strength - new markets drive growth . Focused core competency: Sample and assay technologies . Four Markets: Life Sciences Academia Pharma Research & Development Applied Testing Forensics Veterinary Other Molecular Diagnostics SAMPLE TECHNOLOGIES ASSAY TECHNOLOGIES Sample Assay |
    Sample
& Assay Technologies - 20 - QIAGEN/Digene – Creating a Leader in MDx Creating a Global Leader in Molecular Diagnostics Who is QIAGEN? What is our strategy? What do we do in Diagnostics? |
 Sample
& Assay Technologies - 21 - QIAGEN/Digene – Creating a Leader in MDx Molecular Diagnostics Growth Strategy Multiple, Synergistic Channels – Focused Direct Sales Resources Direct sales OEM development OEM sales . Direct Sales Growing direct sales force > 150 - 160 (1) Focus on pathogens Market leader in developing countries China – strong #2 . OEM Products Integrated solutions, CE and FDA Assays, preanalytical, automation > 15 Partners Developing solutions for partners (1) NA 23, EU 28, Rest Asia Sample Assay MDx |
 Sample
& Assay Technologies - 22 - QIAGEN/Digene – Creating a Leader in MDx QIAGEN Has Developed More Than 30 PCR Assays Cytomegalovirus Dengue virus Epstein-Barr virus Enterovirus Hepatitis A virus Hepatitis B virus Human immunodefienciy virus-1 Herpex simplex virus Influenzavirus Influenzavirus H5 (Avian flu) Orthopoxvirus Parvovirus B19 SARS-Coronavirus Varicella Zoster virus West Nile virus Bacillus antrhacis Borrelia spec. Campylobacter spec Chlamydia trachomatis Listeria monocytogeneses Mycobacterium paratuberculosis Mycobacterium tub. diff. Mycobacterium Mycoplaxma pneumoniae Salmonella spec. Viruses Bacteria Parasites Pharmacogenetics DPD PCR kit MTHFR PCR kit TPMT PCR kit Plasmodium spec Representative but not complete list Strength: Sensitivity and Specificity Sample Assay MDx |
         Sample
& Assay Technologies QIAGEN – Digene: Creating a Leader in MDx, June 4, 2007 - 23 - QIAplex: Novel and Innovative Multiplex Technology Sample Assay MDx Syndrome “Patient Presentation” Selected qPCR Test Confirmed Pathogen ID Potential Pathogens hMPV hMPV Selection of test for one potential pathogen QIAplex Panel SARS Avian Flu RSVA RSVB hMPV PIVI PIVII Ent Rhino Coxsac kie SARS Avian Flu RSVA RSVB hMPV PIVI PIVII Ent Rhino Coxsackie Multiplexing: Screening Technology qPCR: High resolution confirmation/quantification |
 Sample
& Assay Technologies - 24 - QIAGEN/Digene – Creating a Leader in MDx Tangible Opportunities for Future Growth Synergies Significant Growth Synergies Exciting near-term product synergies: Multiplexing technologies for future genotyping application Sample preparation Next-generation assay technologies Assay breadth in woman’s health Exciting other synergies include: QIAGEN is key supplier to vaccine developers Manufacturing capacity Channel lends itself to many future assay opportunities FastHPV platform in developing countries, QIAGEN has channel Next generation instrumentation And many more to come… |
 Sample
& Assay Technologies - 25 - QIAGEN/Digene – Creating a Leader in MDx QIAGEN and Digene 15 year partnership in Molecular Diagnostics >15 year partnership between QIAGEN and Digene Digene products leverage QIAGEN sample and assay technologies Example: RapidCapture system Core platform of Digene FDA approved solution, used in HPV testing Digene sole marketer Next generation platform development programs Partnership – Similar cultures – Focus - Excellence |
 Sample
& Assay Technologies - 26 - QIAGEN/Digene – Creating a Leader in MDx QIAGEN and Digene - Direct Neighbors Germantown and Gaithersburg MD Companies are 5 minutes apart (2.8 miles) |
    Sample
& Assay Technologies - 27 - QIAGEN/Digene – Creating a Leader in MDx The Combination Creates Real Value For All Market and technology leader in molecular diagnostics*) over $350 million of molecular diagnostics revenue Targeting > $800 million in total revenues in 2008 Unique technology and product portfolio Fastest growing product portfolio; Most complete technology portfolio Absolute leader in key >$1 billion HPV segment Most powerful sales and marketing channel to realize technology potential Over 300 professionals in MDx marketing and sales Over 1000 overall sales and marketing professionals Excellent basis for future expansion and growth Truly global sales and marketing presence Leading technologies and R&D World class capabilities and organization to ensure success Compelling financial profile and value creation opportunity Enhanced growth profile and combined profitability QIAGEN’s Breadth and Platforms +
Digene’s Content *) Ex blood banks and viral load VAL UE |
 Sample
& Assay Technologies - 28 - QIAGEN/Digene – Creating a Leader in MDx The Combination Accelerates QIAGEN’s Molecular Strategy Digene’s highly focused strategy in MDx is a unique fit with QIAGEN QIAGEN’s strategy: leadership in “Sample & Assay Technologies”
– in research, pharma, applied testing and MDx Same target customers in MDx Superb brands and reputations HPV testing is fastest growing, large segment in MDx with over $1 billion market potential Digene’s strong IP positions in HPV – over 70 subtypes HPV bridges QIAGEN’s virology leadership into emerging, fast growing oncology segment Important HPV assay creates unique value for QIAGEN’s platforms and assay breadth . Leading regulatory expertise – only FDA approved test for HPV Great fit with QIAGEN’s emerging pipeline . Enhanced growth profile and combined profitability leads to
strong value creation QIAGEN’s Breadth and Platforms +
Digene’s Content |
 Sample
& Assay Technologies - 29 - QIAGEN/Digene – Creating a Leader in MDx The Combination Accelerates Digene’s Development Goals QIAGEN’s unparalleled sample and assay technology breadth creates opportunities for future: Adds key assay technologies such as multiplexing (QIAplex), PCR, isothermal technologies Adds key sample technologies such as DNA processing from cervical swabs QIAGEN’s broad assay portfolio offers new value for Digene’s customers and Next generation platform programs QIAGEN’s global sales strength accelerates rapid and global rollout Digene can take advantage of QIAGEN’s operations and infrastructure which are needed for next phase of growth QIAGEN’s Breadth and Platforms + Digene’s Content |
 Sample
& Assay Technologies - 30 - QIAGEN/Digene – Creating a Leader in MDx World-Class Capabilities & Organization Ensure Success Great breadth and depth of management team Strong leaders from both companies Leading expertise in molecular diagnostics and life sciences Strong foundation for collaboration built upon 15-year partnership Similar cultures and strong working relationship Strong synergies – growth allows retention of talent base Integration plan well-developed 12 month process, clear timelines Mirrored teams Being neighbors a big advantage Maryland: headquarters of MDx business QIAGEN has proven track record in very successfully integrating – 12 companies in last 3 years. We are Huge Growth Potential - Increasing Awareness |
    Sample
& Assay Technologies - 31 - For Internal Use Only Four Phases to an effective Integration of Digene Phase 0 Pre-Process planning Phase 2 Detailed planning & decision making Phase 3 Implementation & execution Phase 1 Issue identification and action planning Appoint and launch integration teams Communicate Stabilize the business Establish resource baselines for both companies Identify key integration issues and areas for synergy realization Communication Identify integration opportunities Develop/decide on future business structure Validate plans in detail Initiate execution of short term actions Return first units to “business-as-usual” Finalize Budget 2008 Communicate Resolve open issues Implementing decisions Monitor target achievement Manage as single company Communicate Define integration process and timeline Define integration approach & responsibilities Plan, plan, plan Agree on integration resources, project teams, charter & external support Develop organizational and core operating model Determine targets Communication “Pre-closing” “Plan Budget 2008” "Achievements" “Pre-annoucement/ Pre-closing” Day of public announcement Ca. September 2007 December 2007 June 2008 |
 Sample
& Assay Technologies - 32 - QIAGEN/Digene – Creating a Leader in MDx Integration should be accomplished in 6 – 12 months 10 20 30 40 50 10 20 30 40 50 Load dependent on requirements Handover Resources FTE Integration Accomplished Line function Take over responsibilities Jul Jun May Mar Apr Jan Feb May Jun Jul Oct Nov Aug Sep Dec Aug Sep Apr Line function responsible Integration Project Functional project In transition Announcement 3. June Closing Announce- ment Pre- Planing Closing New Budget 2008 Pre- Closing Post- Closing Implementation |
 Sample
& Assay Technologies - 33 - QIAGEN/Digene – Creating a Leader in MDx Project Structure for Integration Special Projects Functional Projects Business Projects Responsible for the bulk of the integration Made up from representatives of the different functions of both companies Develop guide-lines to ensure consistency around the world Responsible for planning and tracking the overall process Help to identify and resolve emerging issues Responsible for leading the integration process Divestments & Acquisition New mission & Steering principles Locations / Property Brand management HR IT Manufacturing R&D Regulatory Administration Marketing Asia Marketing Europe Marketing USA, Americas Global Product Management Distributor Sales Europe Sales Asia Sales USA, Americas Integration office Communication . Doug Liu Joe Slattery Doug White Thomas
Schweins Project Team Steering Committee Peer Schatz Daryl Faulkner |
 Sample
& Assay Technologies - 34 - QIAGEN/Digene – Creating a Leader in MDx Doug Liu – VP Global Operations – QIAGEN Douglas Liu VP Global Operations Doug Liu joined QIAGEN in 2005 MBA from Boston University Science degree from the University of Illinois Multifunctional background in diagnostic Industry Operations Strategic planning and R&D . 20 years track record of success in Molecular diagnostics Bayer Operation Head - Nucleic Acid Diagnostics Bayer Strategic Planning and Consulting Abbott Diagnostics Chiron Diagnostics |
 Sample
& Assay Technologies - 35 - QIAGEN/Digene – Creating a Leader in MDx Doug White – SVP Sales & Marketing – Digene Douglas White SVP Sales & Marketing Americas and Asia Pacific . Doug White joined Digene in 2003 Started as VP Sales & Marketing North America Oversees commercial operations incl. Sales, Marketing Service and Support Americas and Asia Pacific . 20 years of sales & marketing experience in health care . 10 years track record of success in Molecular diagnostics SVP Global Marketing at Roche Molecular Systems VP Sales & Marketing at Bayer Vice President of US Marketing at Chiron Abbott Diagnostics |
 Sample
& Assay Technologies - 36 - QIAGEN/Digene – Creating a Leader in MDx Joseph P. Slattery Chief Financial Officer and Senior Vice President . Joe Slattery joined Digene in 1996 Corporation’s finance, accounting, investor relations, treasury, information systems program management operations Mr. Slattery was appointed Chief Financial Officer Oct 2006. . Prior to Digene, Joe worked in public accounting KPMG Peat Marwick Ernst & Young LLP . He received a B.S. in accounting from Bentley College and is a certified public accountant. Joe Slattery – Chief Financial Officer Digene |
 Sample
& Assay Technologies - 37 - QIAGEN/Digene – Creating a Leader in MDx Thomas Schweins VP Marketing & Strategy Thomas Schweins – VP Marketing & Strategy QIAGEN . Thomas Schweins joined QIAGEN in 2004 Biochemistry, University Hannover Business Adminstration, USC Los Angeles PhD, Max Planck Institute, Heidelberg . Multifunctional background in Life Science Industry Strategy and Strategic Planning Marketing R&D Post-Merger-Integration . 15 years track record of success in Life Sciences Senior Manager Boston Consulting Group Senior Project Manager Aventis Technology & Business Dev Manager Hoechst |
 Sample
& Assay Technologies QIAGEN – Digene: Creating a Leader in MDx, June 4, 2007 - 38 - Questions and Answers If you have further questions: Call +240-686 7362 E-mail Merger@qiagen.com |
Disclaimer Regarding Forward-Looking Statements
Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of QIAGEN’s products, the timing of the completion of the transaction between QIAGEN and Digene, the anticipated benefits of the business combination transaction involving QIAGEN and Digene, including future financial and operating results, the expected financing for the transaction, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. QIAGEN and Digene caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. These include risks and uncertainties relating to: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the parties may be unable to complete the transaction because conditions to the closing of the transaction may not be satisfied; the risk that the businesses will not be integrated successfully; the transaction may involve unexpected costs or unexpected liabilities; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations. In addition, the transaction will require the combined company to obtain significant financing. The combined company’s liquidity and results of operations could be materially adversely affected if such financing is not available on favorable terms.
Moreover, the substantial leverage resulting from such financing will subject the combined company’s business to additional risks and uncertainties. The risks included above are not exhaustive. The most recent reports on Form 20-F, Form 6-K and other periodic reports filed with or furnished to the Securities and Exchange Commission by QIAGEN and the most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Digene with the Securities and Exchange Commission contain additional factors that could impact the combined company’s businesses and financial performance. The parties expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties’ expectations or any change in events, conditions or circumstances on which any such statement is based.
Additional Information
QIAGEN is filing today a Current Report on Form 6-K that will include as exhibits the Agreement and Plan of Merger among QIAGEN, QIAGEN North American Holdings, Inc., QIAGEN’s merger subsidiary and Digene Corporation. QIAGEN intends to file a Registration Statement on Form F-4 and a Schedule TO, and Digene plans to file a Solicitation/Recommendation Statement on Schedule 14D-9, with the Securities and Exchange Commission in connection with the transaction. QIAGEN and Digene expect to mail a Prospectus, which is part of the Registration Statement on Form F-4, the Solicitation/Recommendation Statement on Schedule 14D-9 and related exchange offer materials, including a letter of election and transmittal, to shareholders of Digene upon commencement of the exchange offer. These documents contain important information about the transaction and should be read before any decision is made with respect to the exchange offer. Investors and stockholders will be able to obtain free copies of these documents through the website maintained by the Securities and Exchange Commission at www.sec.gov. Free copies of these documents may also be obtained from QIAGEN, by directing a request to QIAGEN’s IR department at QIAGEN Strasse 1, 40724 Hilden, Germany, or from Digene, by directing a request to Digene at 1201 Clopper Road, Gaithersburg, MD, 20878.
In addition to the Registration Statement on Form F-4, Schedule TO, Prospectus, Solicitation/Recommendation Statement on Schedule 14D-9 and related exchange offer materials, both QIAGEN and Digene file or furnish annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission. You may read and copy any reports, statements or other information filed or furnished by QIAGEN or Digene at the SEC’s Public Reference Room at Station Place, 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. QIAGEN’s and Digene’s SEC filings are also available to the public at the SEC’s web site at http://www.sec.gov, or at their web sites at www.qiagen.com or www.digene.com.